Not long ago, Pfizer said it was getting out of the business of developing drugs for Parkinson’s and Alzheimer’s diseases, but the pharmaceutical giant appears to be hedging its bets.

Pfizer and Bain Capital, the Boston global investment firm cofounded by Mitt Romney, plan to announce Tuesday that they are launching a biopharmaceutical startup that will work on medicines for people with Parkinson’s, Alzheimer’s, and other diseases of the central nervous system. The new firm, Cerevel Therapeutics, will be located in the Boston area, but Bain officials did not say where.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy